Who Decided This Cancer Drug Costs $477,600?

The power to say no

The list price is where the story starts, not where it ends.

Once a manufacturer list price is public, health plans and pharmacy benefit managers begin negotiating from it. They can ask for a rebate in exchange for better coverage, lower patient cost sharing, or fewer restrictions.

Their leverage comes from the power to say no—or at least to make that threat credible. If several drugs treat the same patients, a plan can favor a rival. The manufacturer then has a reason to lower its net price.

Rasonque is harder to bargain over. It has few substitutes, and Medicare treats cancer drugs as a protected class under Part D. Plans generally must cover all or substantially all cancer drugs. That protects patients from losing access. It also weakens the threat that often forces a deeper discount.

The final contracts stay private. We do not know what Revolution Medicines has offered each payer or what any payer will ultimately pay for Rasonque.

The public sees the list price. Each payer sees its own net price. The patient sees the terms of one insurance plan. No one outside the deal gets the whole picture.

This matters far beyond one drug. IQVIA estimates that oncology remained pharma's largest therapeutic market in 2025, with $291 billion in global spending measured at ex-manufacturer list prices. Oncology also accounted for 41% of all clinical trials in 2024. I think the way we price cancer drugs is part of why so much of the industry's capital flows there.

Expensive compared with what?

Rasonque's annualized list price is not the largest sticker price in medicine.

Several one-time gene therapies launched at multiples of it. Lenmeldy, for certain children with metachromatic leukodystrophy, launched at $4.25 million. Hemgenix, for adults with hemophilia B, launched at $3.5 million. Elevidys, for Duchenne muscular dystrophy, launched at $3.2 million; the FDA has since narrowed its use after reports of fatal liver injury. Lyfgenia and Casgevy, both approved for sickle cell disease, launched at $3.1 million and $2.2 million.

A one-time therapy aims to create a durable benefit and concentrates its cost in one dose. A recurring drug spreads its cost across months or years. Price per dose can make the one-time therapy look categorically more expensive even when a chronic treatment eventually costs as much or more.

Consider two recurring treatments for rare genetic diseases. At the list prices used in independent reviews, Trikafta for cystic fibrosis cost $311,741 per year. Spinraza for spinal muscular atrophy cost $750,000 in the first year and $375,000 each year after. Five years of Spinraza would total about $2.25 million before rebates or the costs of other care, essentially matching the one-time gene therapies.

Even a lifetime estimate is unstable. The PCSK9 cholesterol drugs launched in 2015 at about $14,000 per year; three years later, Amgen cut Repatha's list price by 60%.

The prices of one dose, one year, and a lifetime of treatment answer different questions. The number of people eligible for the drug matters too: a medicine for millions of people has a different budget impact than one for a rare disease, even when its price per patient is lower.

The closer comparison is other cancer pills

Among oral cancer treatments, Rasonque stands out. It is not a one-time treatment, but it is not usually a lifelong one either. Patients take a drug like Rasonque until the cancer progresses or the side effects become too severe. In the trial, that was a median of 6.2 months.

A fairer comparison is other targeted cancer pills. A 2025 JAMA study found that self-administered targeted cancer drugs launched from 2023 through 2025 at a mean of $27,891 per month, in 2025 dollars. Rasonque launched at $39,800, about 43% above that mean.

What is the price of a little more time?

The headline arithmetic is tempting: put a roughly $246,760 list-price treatment course beside a 6.5-month gap in median survival and ask what each extra month cost.

But those figures cannot answer that question. The 6.5 months are the difference between two group medians, not what each person gained. The $246,760 combines a median treatment duration with a public list price, not the net amount an insurer paid. Dividing one by the other would produce a clean number, not a reliable estimate of value.

The fair question is what changed for patients during that time.

In RASolute 302, median time before the cancer progressed was 7.2 months with daraxonrasib and 3.6 months with chemotherapy. In analyses that counted death as deterioration, patients went longer before their pain worsened, 9.2 months versus 3.8, and before their reported health and quality of life declined, 5.7 months versus 2.6.

Daraxonrasib is not an easy drug to take. Rash, diarrhea, mouth sores, nausea, and vomiting were common, and the FDA label includes several serious warnings. But severe treatment-related side effects were less common than with chemotherapy. Only 1.2% of patients stopped daraxonrasib because of one, compared with 11.2% on chemotherapy.

These are the pieces a credible cost-effectiveness analysis would have to use: the full survival curves, quality of life over time, the net price, and the costs of treatment and side-effect care. Health economists often combine survival and quality of life into a quality-adjusted life year, or QALY, but no independent analysis has yet done that for daraxonrasib.

For a family facing pancreatic cancer, a few more weeks before pain worsens can matter enormously. That does not make the drug priceless. It makes the case for a defensible price more important.

What the public should be able to see

The problem is not that a good cancer drug costs money. It is that no one outside the deal can explain why a certain price is the right price.

Daraxonrasib produced a meaningful result for people whose pancreatic cancer had already progressed. A drug that extends life after other treatment has stopped working should be worth more than one with a small or uncertain benefit. But valuable cannot mean any price the manufacturer chooses.

We should be able to see the case for the price. An independent review could weigh survival, quality of life, side effects, the strength of the evidence, and the other treatments available.

A net price should change as the evidence changes. It could begin as provisional, then be reviewed as survival data mature or the drug moves into new cancers and earlier treatment. When we can measure results outside a trial, rebates could depend on whether the promised benefit appears in practice.

And the patient's own bill should have a firm cap. The sick person should never become the bargaining tool.

We can see the science. We can see the survival result. We can see the list price. What we cannot see is how one became the other.

Hillary Lin, MD
Founder & CEO, CareCore